What do systematic reviews say?

Platinum‐containing chemotherapy vs chemotherapy without platinum

Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).

• Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
  HR 0.7 [0.5, 0.96]
  4 studies · 1256 participants
  High

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 183 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

Summary of findings table ‐ Systemic therapy showed no clear difference in change in grip strength from baseline to end of intervention compared with control (low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 1.08 [0.37, 3.17]
  1 study · 137 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 344 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

Summary of findings table ‐ Systemic therapy showed no clear difference in effect on discontinuation of aromatase inhibitors (AI) compared with control (low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 0.16 [0.01, 2.99]
  1 study · 147 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 44 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

It is very uncertain whether summary of findings table ‐ Systemic therapy changes incidence of AIMSS compared with control (very low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 0.82 [0.63, 1.06]
  2 studies · 240 participants
  Very low

Prophylactic CPAP vs very early CPAP

It is very uncertain whether prophylactic CPAP changes bronchopulmonary dysplasia at 28 days compared with very early CPAP (very low certainty).

• Prophylactic or very early initiation of continuous positive airway pressure (CPAP) for preterm infants 2021 · Cochrane Headline outcomes only
  RR 0.5 [0.05, 5.27]
  1 study · 72 participants
  Very low

Prophylactic CPAP vs very early CPAP

The review found no eligible studies for this question.

• Prophylactic or very early initiation of continuous positive airway pressure (CPAP) for preterm infants 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Prophylactic CPAP vs very early CPAP

It is very uncertain whether prophylactic CPAP changes death at any time (by 28 days) compared with very early CPAP (very low certainty).

• Prophylactic or very early initiation of continuous positive airway pressure (CPAP) for preterm infants 2021 · Cochrane Headline outcomes only
  RR 0.75 [0.29, 1.94]
  1 study · 72 participants
  Very low

Prophylactic CPAP vs very early CPAP

The review found no eligible studies for this question.

• Prophylactic or very early initiation of continuous positive airway pressure (CPAP) for preterm infants 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Prophylactic CPAP vs very early CPAP

• Prophylactic or very early initiation of continuous positive airway pressure (CPAP) for preterm infants 2021 · Cochrane Headline outcomes only
  no estimate extracted
  72 participants
  GRADE not reported

Prophylactic CPAP vs very early CPAP

The review found no eligible studies for this question.

• Prophylactic or very early initiation of continuous positive airway pressure (CPAP) for preterm infants 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Prophylactic CPAP vs very early CPAP

The review found no eligible studies for this question.

• Prophylactic or very early initiation of continuous positive airway pressure (CPAP) for preterm infants 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Heparin prophylaxis vs no treatment/placebo

The review found no eligible studies for this question.

• Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

LMWH prophylaxis vs UFH

It is very uncertain whether antenatal (± postnatal) prophylaxis: LMWH changes adverse effects sufficient to stop treatment compared with UFH (very low certainty).

• Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period 2021 · Cochrane Headline outcomes only
  RR 0.07 [0.01, 0.54]
  2 studies · 226 participants
  Very low

Heparin prophylaxis vs no treatment/placebo

It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic thromboembolic events ( compared with no treatment/placebo (very low certainty).

• Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period 2021 · Cochrane Headline outcomes only
  RR 0.39 [0.08, 1.98]
  4 studies · 476 participants
  Very low

Postnatal prophylaxis: LMWH vs no treatment/placebo

• Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 24 participants
  Very low

Postnatal prophylaxis: LMWH vs no treatment/placebo

• Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 58 participants
  Very low